CBIO
HEALTHCARECrescent Biopharma Inc
$18.06-0.02 (-0.11%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CBIO Today?
No stock-specific AI insight has been generated for CBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.72$28.00
$18.06
Fundamentals
Market Cap$498M
P/E Ratio—
EPS$-5.88
Dividend Yield—
Dividend / Share—
ROE-1.6%
Profit Margin—
Debt / Equity—
Trading
Volume269K
Avg Volume (10D)—
Shares Outstanding27.6M
CBIO News
20 articles- Crescent Biopharma to Present at May Investor ConferencesYahoo Finance·May 6, 2026
- Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business HighlightsYahoo Finance·Apr 29, 2026
- Crescent Biopharma Announces Grants of Inducement AwardsYahoo Finance·Apr 24, 2026
- Crescent Biopharma: Q4 Earnings SnapshotYahoo Finance·Feb 26, 2026
- Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Feb 26, 2026
- Crescent Biopharma to Present at March Investor ConferencesYahoo Finance·Feb 23, 2026
- Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid TumorsYahoo Finance·Feb 18, 2026
- Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 5, 2026
- Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPAYahoo Finance·Jan 5, 2026
- Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid TumorsYahoo Finance·Jan 5, 2026
- Huge Insider Buying in MGM and Salesforce247 Wall St·Dec 12, 2025
- Crescent and Kelun-Biotech swap cancer asset rights in double dealPharmaceutical-technology·Dec 5, 2025
- Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader useBiopharmadive·Dec 5, 2025
- Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer DrugsYahoo Finance·Dec 4, 2025
- Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid TumorsYahoo Finance·Dec 4, 2025
- Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology TherapeuticsYahoo Finance·Dec 4, 2025
- Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite BioYahoo Finance·Nov 11, 2025
- Crescent Biopharma: Q3 Earnings SnapshotYahoo Finance·Nov 6, 2025
- Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business HighlightsYahoo Finance·Nov 6, 2025
- Crescent Biopharma to Present at November Investor ConferencesYahoo Finance·Nov 5, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$18.08
Day High$0.00
Day Low$0.00
52 Week High$28.00
52 Week Low$8.72
52-Week Range
$8.72$28.00
$18.06
Fundamentals
Market Cap$498M
P/E Ratio—
EPS$-5.88
Dividend Yield—
Dividend / Share—
ROE-1.6%
Profit Margin—
Debt / Equity—
Trading
Volume269K
Avg Volume (10D)—
Shares Outstanding27.6M
About Crescent Biopharma Inc
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement regulation. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—